NeurologyLive’s Post

Big news from Ardelyx is sparking discussions across the biotech world, and for good reason. Their recent FDA approval is a significant milestone, but there's even more to watch in the biopharma landscape. If you're an investor or simply curious about the next big catalysts in biotech, meet Reviva (RVPH) and BioVie (BIVI). RVPH is a well-funded Phase 3 biopharma with an impressive pipeline focused on schizophrenia, depression, and other mental health conditions. RVPH recently completed several prelaunch studies, and the top-line data from its Phase 3 RECOVER study is expected in the coming days. BIVI, another exciting player in the field, is a clinical-stage company with its sights set on addressing unmet medical needs in neurodegeneration, liver disease, and more. Their pipeline includes NE3107 for Alzheimer's and Parkinson's and BIV201 for refractory ascites and HRS-AKI. As the world of biotech continues to advance, RVPH and BIVI are two names to watch. With near-term catalysts, these stocks could soon soar. Learn more and read our disclosures - https://ow.ly/UknM50PY8ki #Biotech #Innovation #Healthcare #RVPH #BIVI #Ardelyx #Biopharma #Investing #ScienceMatters

Experimental drug slows progression of early Alzheimer's disease by 60%, study finds. So say the headlines on one of Europe's news sites. It's been mentioned that Eli Lilly's experimental drug #donanemab slowed the progression of Alzheimer's by 60% for patients in the earliest stages of the brain-wasting disease, according to trial data presented at a medical meeting recently. But is all that it seems? Well, there are many different interpretations of this data. See attached letter from the lastest BMJ which suggests much less exciting outcomes and highlights some of the serious side effects. There are people on here with much more expertise on these matters than I but I find it interesting the way this 'silver bullet' is being discussed in the media currently. #alzheimers #useyournoggin #lifestyle #bmj #clinicalstudies #newdrugs

Last week at the Alzheimer's Association® International Conference #AAIC2023, Eli Lilly and Company shared the results of donanemab's phase 3 trial. They found that the drug significantly slowed cognitive and functional decline in people with early #Alzheimersdisease. But what is donanemab and how does this treatment work? Medical News Today answers that very question about the new #Alzheimers drug in a #brainhealth article released today. Read it now:

A new drug called donanemab is showing promise in the fight against Alzheimer's disease. In a global trial, the drug has been found to slow cognitive decline in patients with early-stage Alzheimer's. Donanemab works by clearing a protein that builds up in the brains of people with Alzheimer's. While it is not a cure, the results mark a new era in treating Alzheimer's. It is currently being assessed by the UK's drugs watchdog for possible NHS use. Read more: https://lnkd.in/gEWSrb-D #medicalscience #Alzheimer #drugdevelopment #biology #medicine

#NEW from #CTAD2023 | Unraveling the #oligomer hypothesis in #Alzheimer’s disease 🎥 🧠 Eric Siemers MD, Acumen Pharmaceuticals, Inc., discusses the decades-long journey to understanding #Alzheimersdisease. Contrary to the longstanding #amyloid hypothesis, recent findings indicate that the soluble #oligomers of #amyloid-β (Aβ) are the toxic molecules, not the Aβ #monomers or #fibrils which constitute #plaques 💡Experiments reveal that these #globularoligomers disrupt long term potentiation, induce #intracellular #calcium influx, and lead to the #hyperphosphorylation of tau 💡The #oligomer hypothesis identifies these soluble oligomers as the key drivers of #Alzheimerspathology, positioning them as the best therapeutic targets 💡ACU193, is an investigation #monoclonalantibody that specifically targets these #oligomers. While the #FDA-approved antibody #lecanemab targets #protofibrils, which differ in shape from #oligomers but shares solubility and #toxicity, #ACU193 stands out as the sole #antibody capable of accurately testing the oligomer hypothesis Take a look 👉 https://lnkd.in/gWgJQ8ZT #Neurology

Great insights Eric Siemers MD

September is World Alzheimer's Month. Current research sets the clinical trial failure rate of Alzheimer's drugs at 99.6%. At Axol, we want to move the dial on this number using the power of human iPSCs. Stay tuned for a month of posts to raise awareness of this increasingly common, debilitating condition and the work we're doing to accelerate and de-risk Alzheimer's drug discovery using human iPSCs. https://hubs.la/Q020FBY60 #iPSCs #AlzheimersDisease #StemCells #DrugDiscovery #ClinicalTrialInADish

As the #pharma industry navigates the impact of the Inflation Reduction Act on drug pricing and #innovation; real-world evidence, propelled by the Cures Act, is becoming increasingly vital for driving strategy and drug development. I wanted to share this older paper we wrote before RWE became a thing, where we discuss the creation of a large real-world data asset focused on the neuroscience therapeutic area. #RealWorldData #RealWorldEvidence #InflationReducionAct #21CCA #CuresAct #DrugDevelopment #Pharmaceuticals #Neuroscience #DataScience #Innovation #BeforeItWasCool Regenstrief Institute, Inc. Brian E Dixon, PhD

Neurotransmitter Transporter’s Structures Suggest New Drug Strategies P.S. If you like this post please 1) Like it (so I know it's useful) and 2) Repost and share it (so others can see it too)

I am very much delighted to share our publication in the journal Drug Discovery Today, https://lnkd.in/enq8HCwP "#CRISPR-Cas9 in Alzheimer’s disease: #Therapeutic trends, modalities, and challenges" resulting from our collaboration with Anupama Chaudhary, Birbal Singh, Saikat Dewanjee, Ramesh Kandimalla. This research paper explores the potential of CRISPR-Cas9 as a therapeutic tool for #Alzheimer's disease (AD), focusing on the current trends, modalities, and challenges associated with its application. #crisprmedicinenews #pharma #geneediting #alzheimers #alzheimersdisease #celltherapy #cellandgenetherapy